Blue Light Cystoscopy and Bladder Cancer Detection

What is it about?

The study conducted by the authors found that Blue light cystoscopy with hexaminolevulinate (HAL) during transurethral resection of bladder cancer (TURBT) improves detection compared to white light cystoscopy, reducing recurrence rates. The study included 101 patients who underwent blue light cystoscopy between July 2017 and November 2020. The study found that blue light cystoscopy with HAL provides superior detection and diagnosis of CIS in patients with previous white light cystoscopy. The study concludes that blue light TURBT with HAL improves detection of CIS with statistical significance and supports multiple studies published in the literature.

Featured Image

Why is it important?

This research is important because it provides evidence for the superiority of blue light cystoscopy with hexaminolevulinate (HAL) in detecting carcinoma in situ (CIS) in patients who have previously undergone white light cystoscopy. The study also identifies the benefits of using blue light cystoscopy in surgical management, as well as its potential role in office-based bladder cancer surveillance. Key Takeaways: 1. Blue light cystoscopy with HAL improves detection of CIS with statistical significance. 2. Blue light cystoscopy has the potential advantage of finding cancer in normal white light cystoscopy. 3. Upstaging to muscle invasive bladder cancer (MIBC) occurred in 3.4% of patients in the blue light re-resection arm. 4. Recurrence rate was 33.3% in the primary arm and 37.5% in the secondary arm after 24 months of follow-up. 5. Blue light TURBT with HAL provides superior detection and diagnosis of CIS in patients with previous white light cystoscopy.